EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes

Anukriti Sharma, Arshiya Mariam, Emily Zacherle, Alex Milinovich, Janine Bauman, David S Sugano, Josh Noone, Jigar R Rajpura, Robert S Zimmerman, Bartolome Burguera, Michael W Kattan, Anita D Misra-Hebert und 2 weitere

Diabetes, Obesity and Metabolism · 2024

DOI: 10.1111/dom.15896 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2024. Verfasst von Anukriti Sharma und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Weight Loss, Glycemic Control, Hypoglycemic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novo Nordisk, Inc, Novo Nordisk.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To investigate the independent contributions of glycated haemoglobin (HbA1c) reduction and weight loss to clinical outcomes in patients with type 2 diabetes (T2D) treated with antidiabetic drugs, including glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs). Materials and Methods This observational, retrospective cohort study used deidentified electronic health record‐derived data from patients evaluated at the Cleveland Clinic (1 January 2000–31 December 2020). Cohort A included 8876 patients with newly diagnosed T2D treated with any of six antidiabetic drug classes. Cohort B included 4161 patients with T2D initiating GLP‐1RA treatment. The effects of body mass index (BMI) and HbA1c reduction, variability, and durability on clinical outcomes were investigated.

Results

In Cohort A, each 1% BMI reduction was associated with 3%, 1%, and 4% reduced risk of heart failure ( p = 0.017), hypertension ( p = 0.006), and insulin initiation ( p = 0.001), respectively. Each 1% (~11 mmol/mol) HbA1c reduction was associated with 4% and 29% reduced risk of hypertension ( p = 0.041) and insulin initiation ( p = 0.001), respectively. In Cohort B, each 1% BMI reduction was associated with 4% and 3% reduced risk of cardiovascular disease ( p = 0.008) and insulin initiation ( p = 0.002), respectively. Each 1% (~11 mmol/mol) HbA1c reduction was associated with 4% and 16% reduced risk of chronic kidney disease ( p = 0.014) and insulin initiation ( p = 1 × 10 −4 ), respectively. Lower BMI variability and greater BMI durability were associated with decreased risk of clinical outcomes in both cohorts.

Conclusions

Antidiabetic medication‐associated, and specifically GLP‐1RA‐associated, weight loss and HbA1c reductions independently reduce real‐world clinical outcome risk.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2Weight LossGlycemic ControlHypoglycemic AgentsGlycated HemoglobinBody Mass IndexHumansMaleFemaleMiddle AgedRetrospective StudiesAgedBlood GlucoseCohort StudiesGlucagon-Like Peptide-1 Receptor Agonists

Stichwörter der Autor:innen

GLP‐1antidiabetic drugobservational studyreal‐world evidencetype 2 diabetes

Substanzen

Hypoglycemic AgentsGlycated HemoglobinBlood Glucosehemoglobin A1c protein, humanGlucagon-Like Peptide-1 Receptor Agonists

Autor:innen und Institutionen

  • Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Center for Quantitative Metabolic Research, Cleveland Clinic, Cleveland, Ohio, USA.
  • Novo Nordisk Inc., Plainsboro, New Jersey, USA.
  • Endocrinology and Metabolism Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Healthcare Delivery and Implementation Science Center, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Kevin M Pantalone, Daniel M Rotroff

Förderung

  • Novo Nordisk, Inc
  • Novo Nordisk

Zitieren

APA

Sharma, A., Mariam, A., Zacherle, E., Milinovich, A., Bauman, J., Sugano, D. S., Noone, J., Rajpura, J. R., Zimmerman, R. S., Burguera, B., Kattan, M. W., Misra-Hebert, A. D., Pantalone, K. M., & Rotroff, D. M. (2024). Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.15896

Vancouver

Sharma A, Mariam A, Zacherle E, Milinovich A, Bauman J, Sugano DS, et al. Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes. Diabetes, Obesity and Metabolism. 2024. doi:10.1111/dom.15896

BibTeX
@article{Sharma2024,
  author = {Sharma, Anukriti and Mariam, Arshiya and Zacherle, Emily and Milinovich, Alex and Bauman, Janine and Sugano, David S and Noone, Josh and Rajpura, Jigar R and Zimmerman, Robert S and Burguera, Bartolome and Kattan, Michael W and Misra-Hebert, Anita D and Pantalone, Kevin M and Rotroff, Daniel M},
  title = {Elucidating the role of weight loss and glycaemic control in patients with type 2 diabetes},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2024},
  doi = {10.1111/dom.15896}
}
Kostenlos starten →